A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Incyte Corporation
Incyte Corporation
The First Affiliated Hospital of Xiamen University
Kaiser Permanente
University of Rochester
Conjupro Biotherapeutics, Inc.
Inmune Bio, Inc.
Vividion Therapeutics, Inc.
Institut Bergonié
Wake Forest University Health Sciences
Washington University School of Medicine
Centre Oscar Lambret
University Hospital, Strasbourg, France
Centre Oscar Lambret
Centre Oscar Lambret
Centre Oscar Lambret
British Columbia Cancer Agency
Children's Hospital of Philadelphia
Hoffmann-La Roche
University of Ulm
Luzerner Kantonsspital
Assistance Publique - Hôpitaux de Paris
Pfizer
Teva Branded Pharmaceutical Products R&D, Inc.
Pheon Therapeutics
Norwegian University of Science and Technology
GlaxoSmithKline
University of Washington
Sanofi
Ocellaris Pharma, Inc.
Bristol-Myers Squibb
Institut Curie
CytomX Therapeutics
Synthorx, Inc, a Sanofi company
Société des Produits Nestlé (SPN)
Shasqi, Inc.
Elevation Oncology
NiKang Therapeutics, Inc.
University of Kentucky
AbbVie
Pfizer
Hoffmann-La Roche
University of California, San Diego
Zymeworks BC Inc.
Astellas Pharma Inc
Wake Forest University Health Sciences
Leap Therapeutics, Inc.
Amgen
AbbVie
BioMed Valley Discoveries, Inc
Prisma Health-Upstate